14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
GCL vs NIVF: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, GCL Global Holdings Ltd (GCL) is the stronger overall head-to-head candidate over NewGenIvf Group Limited Class A (NIVF) in the Tradestie Institutional Equity Comparison Engine, winning 5–3 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Balance Sheet & Cash Flow, R&D & Supply-Chain Moat). GCL carries a Unified Composite Score of 31.6/100 (SELL) at $1.16 (N/M Forward P/E, -5.5% operating margin), whereas NIVF carries 45.8/100 (HOLD) at $0.20 (N/M Forward P/E, -238.2% operating margin).
Composite vs. Pillar Nuance: While NIVF currently prints a higher short-term Unified Composite Score (45.8/100 HOLD vs. GCL 31.6/100 SELL), GCL captures the overall institutional head-to-head verdict (5–3 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (-5.5% vs. -238.2% operating margin) and revenue trajectory (+53.8% vs. -4.7% YoY).
Technical & Structure Timing Caution: GCL trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 70.6); meanwhile NIVF is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 38.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on GCL vs NIVF. Trailing 12-month operating profitability (GCL -5.5% vs NIVF -238.2%) and valuation multiples (GCL N/M vs NIVF N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Medical Care Facilities value chain with $369,508 market capitalization and -238.2% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ GCL vs NIVF Key Questions & Quantitative Answers
As of Nov 16, 2026, GCL Global Holdings Ltd (GCL) is the stronger overall head-to-head candidate over NewGenIvf Group Limited Class A (NIVF) in the Tradestie Institutional Equity Comparison Engine, winning 5–3 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Balance Sheet & Cash Flow, R&D & Supply-Chain Moat). GCL carries a Unified Composite Score of 31.6/100 (SELL) at $1.16 (N/M Forward P/E, -5.5% operating margin), whereas NIVF carries 45.8/100 (HOLD) at $0.20 (N/M Forward P/E, -238.2% operating margin). Composite vs. Pillar Nuance: While NIVF currently prints a higher short-term Unified Composite Score (45.8/100 HOLD vs. GCL 31.6/100 SELL), GCL captures the overall institutional head-to-head verdict (5–3 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (-5.5% vs. -238.2% operating margin) and revenue trajectory (+53.8% vs. -4.7% YoY). Technical & Structure Timing Caution: GCL trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 70.6); meanwhile NIVF is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 38.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
GCL leads the Growth & Scale pillar: GCL posts +53.8% YoY revenue growth and N/A YoY earnings growth on $239M TTM revenue (10.3% gross margin, -5.5% operating margin), compared with NIVF at -4.7% YoY revenue growth and +0.0% YoY earnings growth on $4.6M TTM revenue (23.9% gross margin, -238.2% operating margin). On trailing 12-month operating scale, GCL generates $239M in USD-normalized revenue versus $4.6M for NIVF. In operating R&D and SG&A reinvestment, GCL deploys 15.8% of Rev ($38M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for NIVF.
NIVF screens cheaper on headline valuation multiples. GCL trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 0.6x EV/Revenue (-4.9% EBITDA margin), whereas NIVF trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 0.1x EV/Revenue (unreported EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against GCL (-67.3% ROE) versus NIVF (5.5% ROE) capital efficiency.
In options market volatility and institutional positioning, GCL carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.52β · 75% Vol realized risk). By comparison, NIVF carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.07β · 3093% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.